GLP-1 and the cardiovascular system - PubMed
6 days ago
- #GLP-1
- #incretin therapy
- #cardiovascular system
- GLP-1 is an incretin hormone with significant effects on glucose metabolism.
- DPP-4 inhibitors extend the half-life of GLP-1 but show no reduction in cardiovascular events despite being safe.
- GLP-1 receptor agonists (GLP-1RAs) like liraglutide, semaglutide, and dulaglutide have demonstrated reductions in cardiovascular outcomes.
- Recent advancements have led to the development of orally available GLP-1RAs, expanding treatment options.
- Tirzepatide, a dual GLP-1R and GIPR agonist, shows greater HbA1c reduction and weight loss compared to GLP-1RAs alone.
- Ongoing cardiovascular outcomes trials are evaluating the effects of tirzepatide on hard cardiovascular endpoints.